Satellos Bioscience IncMSCL
Price$8.50

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$24.9MTTM through 31 Dec 2025
Free Cash Flow -$23.6MTTM through 31 Dec 2025

Margins

Current

Returns

-40.3%ROE
-37.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio16.48x
Net Debt-$69.9Mnet cash position
Cash & Equivalents$9.8M

Quality Metrics

Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Skeletal Muscle Regeneration$0
View details

BASECAMP enrollment is on track to complete in Q3 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.